{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:19:49Z","timestamp":1784690389425,"version":"3.55.0"},"reference-count":437,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["dldjournalonline.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.dld.2017.01.141","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T19:30:33Z","timestamp":1484681433000},"page":"338-358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)"],"prefix":"10.1016","volume":"49","author":[{"given":"Livia","family":"Biancone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vito","family":"Annese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandro","family":"Ardizzone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Caprioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Castiglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Comberlato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cottone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Daperno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"D\u2019Inc\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Frieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Fries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gionchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Latella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Milla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrogio","family":"Orlando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Papi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelina","family":"Petruzziello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Riegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Rizzello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Saibeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lia","family":"Scribano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Vecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Vernia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmichele","family":"Meucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Aratari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Bossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cappello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cassinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Chiriatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gionata","family":"Fiorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Formica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Guidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Losco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Mocciaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Onali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Pastorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Pica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariabeatrice","family":"Principi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Renna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rispo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Rogai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Sarmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Scaldaferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosy","family":"Tambasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Viscido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2017.01.141_bib0005","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/0016-5085(79)90385-8","article-title":"National Cooperative Crohn\u2019s Disease Study: results of drug treatment","volume":"77","author":"Summers","year":"1979","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0010","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0016-5085(84)90409-8","article-title":"European Co-operative Crohn\u2019s Disease Study (ECCDS): results of drug treatment","volume":"86","author":"Malchow","year":"1984","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0015","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1136\/bmj.2.4947.1041","article-title":"Cortisone in ulcerative colitis; final report on a therapeutic trial","volume":"2","author":"Truelove","year":"1955","journal-title":"British Medical Journal"},{"key":"10.1016\/j.dld.2017.01.141_bib0020","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/00004836-199002000-00011","article-title":"High-dose methylprednisolone in the treatment of active ulcerative colitis","volume":"12","author":"Rosenberg","year":"1990","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0025","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1572-0241.2006.01007.x","article-title":"Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial","volume":"102","author":"Bossa","year":"2007","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0030","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib0035","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.crohns.2012.09.002","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management","volume":"6","author":"Dignass","year":"2012","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib0040","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/00004836-199412000-00003","article-title":"A randomized, double-blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn\u2019s colitis and ileocolitis","volume":"19","author":"Tremaine","year":"1994","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0045","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/0016-5085(93)90337-C","article-title":"Mesalamine capsules for the treatment of active Crohn\u2019s disease: results of a 16-week trial","volume":"104","author":"Singleton","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0050","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1136\/gut.48.2.186","article-title":"Switch from systemic steroids to budesonide in steroid dependent patients with inactive Crohn\u2019s disease","volume":"48","author":"Cortot","year":"2001","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib0055","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1111\/j.1572-0241.2005.41992.x","article-title":"Budesonide for maintenance of remission in patients with Crohn\u2019s disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials","volume":"100","author":"Sandborn","year":"2005","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0060","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1046\/j.1365-2036.2003.01609.x","article-title":"Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study","volume":"17","author":"Campieri","year":"2003","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0065","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1136\/gut.32.9.1071","article-title":"Double-blind, placebo-controlled trial of metronidazole in Crohn\u2019s disease","volume":"32","author":"Sutherland","year":"1991","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib0070","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1572-0241.1999.935_q.x","article-title":"A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn\u2019s disease","volume":"94","author":"Colombel","year":"1999","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0075","first-page":"328","article-title":"An antibiotic regimen for the treatment of active Crohn\u2019s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin","volume":"91","author":"Prantera","year":"1996","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0080","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1136\/gut.37.5.674","article-title":"A controlled double blind study of azathioprine in the management of Crohn\u2019s disease","volume":"37","author":"Candy","year":"1995","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib0085","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1053\/j.gastro.2005.03.031","article-title":"A randomized, double-blind, controlled withdrawal trial in Crohn\u2019s disease patients in long-term remission on azathioprine","volume":"128","author":"L\u00e9mann","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0090","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/S0140-6736(71)90268-6","article-title":"Controlled trial of azathioprine in Crohn\u2019s disease","volume":"ii","author":"Willoughby","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.01.141_bib0095","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/BF01070829","article-title":"A controlled trial of azathioprine in Crohn\u2019s disease","volume":"20","author":"Rosenberg","year":"1975","journal-title":"American Journal of Digestive Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib0100","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(78)92524-2","article-title":"Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn\u2019s disease","volume":"ii","author":"O\u2019Donoghue","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.01.141_bib0105","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJM200006013422202","article-title":"A comparison of methotrexate with placebo for the maintenance of remission in Crohn\u2019s disease. North American Crohn\u2019s Study Group Investigators","volume":"342","author":"Feagan","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0110","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1053\/gast.2001.23983","article-title":"Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis","volume":"120","author":"D\u2019Haens","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0115","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0016-5085(03)01214-9","article-title":"Randomized, double-blind comparison of 4mg\/kg versus 2mg\/kg intravenous cyclosporine in severe ulcerative colitis","volume":"125","author":"Van Assche","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0120","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0016-5085(95)90277-5","article-title":"Treatment of Crohn\u2019s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)","volume":"109","author":"van Dullemen","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0125","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","article-title":"A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group","volume":"337","author":"Targan","year":"1997","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0130","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/gut.2008.155812","article-title":"Long-term outcome of treatment with infliximab in 614 patients with Crohn\u2019s disease: results from a single-centre cohort","volume":"58","author":"Schnitzler","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib0135","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0140","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/j.gastro.2005.11.030","article-title":"Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn\u2019s disease: the CLASSIC-I trial","volume":"130","author":"Hanauer","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0145","doi-asserted-by":"publisher","first-page":"829","DOI":"10.7326\/0003-4819-146-12-200706190-00159","article-title":"Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial","volume":"146","author":"Sandborn","year":"2007","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0150","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0155","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0160","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/apt.13402","article-title":"Review article: pharmacological aspects of anti-TNF infliximab biosimilars in inflammatory bowel diseases","volume":"42","author":"Papamichael","year":"2015","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0165","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.autrev.2014.02.004","article-title":"The use of biosimilars in immune-mediated disease: a joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper","volume":"13","author":"Fiorino","year":"2014","journal-title":"Autoimmunity Reviews"},{"issue":"8","key":"10.1016\/j.dld.2017.01.141_bib0170","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0175","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ibd.21048","article-title":"World Gastroenterology Organization practice guidelines for the diagnosis and management of IBD in 2010","volume":"16","author":"Bernstein","year":"2010","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib0180","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.dld.2010.07.010","article-title":"The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guidelines: the use of tumor necrosis factor-alpha antagonist therapy in inflammatory bowel disease","volume":"43","author":"Orlando","year":"2011","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2017.01.141_bib0185","unstructured":"OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine 2011; http:\/\/www.cebm.net\/1433 index.aspx?o=5653."},{"key":"10.1016\/j.dld.2017.01.141_bib0190","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.0954-6820.1942.tb06841.x","article-title":"Salazypyrin, a new sulfanilamide preparation. A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation","volume":"110","author":"Svartz","year":"1942","journal-title":"Acta Medica Scandinavica"},{"key":"10.1016\/j.dld.2017.01.141_bib0195","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(77)90831-5","article-title":"An experiment to determine the active therapeutic moiety of sulphasalazine","volume":"2","author":"Azad Khan","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.01.141_bib0200","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.0269-2813.2004.01827.x","article-title":"Systematic review: short term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis","volume":"19","author":"Loftus","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0205","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000543.pub3","article-title":"Oral aminosalicylic acid for induction of remission 1444 in ulcerative colitis (Review)","volume":"10","author":"Feagan","year":"2012","journal-title":"Cochrane Database of Systematic Review"},{"key":"10.1016\/j.dld.2017.01.141_bib0210","first-page":"2031","article-title":"Are there any differences in the efficacy and safety of different formulations of oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? Evidence from Cochrane reviews","volume":"19","author":"Feagan","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib0215","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1053\/j.gastro.2006.10.011","article-title":"Once daily, high concentration MMX mesalamine in active ulcerative colitis","volume":"132","author":"Kamm","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0220","first-page":"2438","article-title":"Diffuse alopecia as side effect of mesalazine therapy in Crohn\u2019s disease","volume":"125","author":"Netzer","year":"1995","journal-title":"Schweizerische Medizinische Wochenschrift"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2017.01.141_bib0225","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-198600321-00003","article-title":"Sulphasalazine: a review of 40 years\u2019 experience","volume":"32","author":"Watkinson","year":"1986","journal-title":"Drugs"},{"key":"10.1016\/j.dld.2017.01.141_bib0230","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0002-9343(86)90562-0","article-title":"Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy","volume":"81","author":"Poland","year":"1986","journal-title":"American Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0235","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1001\/jama.239.24.2590","article-title":"Sulfasalazine toxic reactions. Hepatitis, fever, and skin rash with hypocomplementemia and immune complexes","volume":"239","author":"Mihas","year":"1978","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2017.01.141_bib0240","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1445-5994.1982.tb02433.x","article-title":"Combined hepatotoxicity and neurotoxicity following sulphasalazine administration","volume":"12","author":"Smith","year":"1982","journal-title":"Australian and New Zealand Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0245","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1056\/NEJM196903062801006","article-title":"Sulfapyridine-induced serum sickness-like syndrome associated with plasmacytosis, lymphocytosis and multiclonal gamma-globulinopathy","volume":"280","author":"Han","year":"1969","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0250","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJM195804032581404","article-title":"Focal hepatitis, fever and skin rash following therapy with sulfamethoxypyridazine, a long-acting sulfonamide","volume":"258","author":"Tisdale","year":"1958","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0255","first-page":"271","article-title":"Pancreatitis and pancreatic necrosis during sulfasalazine therapy","volume":"70","author":"Faintuch","year":"1985","journal-title":"International Surgery"},{"key":"10.1016\/j.dld.2017.01.141_bib0260","first-page":"789","article-title":"Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis","volume":"89","author":"Rubin","year":"1994","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0265","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/00005176-199405000-00015","article-title":"Pancreatitis associated with olsalazine and sulfasalazine in children with ulcerative colitis","volume":"18","author":"Garau","year":"1994","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.1016\/j.dld.2017.01.141_bib0270","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/00004836-199412000-00024","article-title":"Sulfasalazine, 5-ASA and acute pancreatitis in Crohn\u2019s disease","volume":"19","author":"Debongnie","year":"1994","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0275","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/j.1572-0241.2004.04123.x","article-title":"Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine treatment and risk of acute pancreatitis: a population-based case-control study","volume":"99","author":"Munk","year":"2004","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0280","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1046\/j.1365-2036.2003.01485.x","article-title":"Discrepancies between population-based data and adverse reaction reports in assessing drugs as causes of acute pancreatitis","volume":"17","author":"Lancashire","year":"2003","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0285","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1111\/apt.12461","article-title":"Drug-induced acute pancreatitis: results from the hospital-based Berlin case-control surveillance study of 102 cases","volume":"38","author":"Douros","year":"2013","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0290","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/0016-5085(80)90689-7","article-title":"Drug-induced pancreatitis: a critical review","volume":"78","author":"Mallory","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0295","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1056\/NEJM197002122820710","article-title":"Pancreatitis as an adverse reaction to salicylazosulfapyridine","volume":"282","author":"Block","year":"1970","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0300","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJM197309062891001","article-title":"Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype","volume":"289","author":"Das","year":"1973","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0305","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/0140-6736(91)92973-6","article-title":"Mesalazine associated thrombocytopenia","volume":"337","author":"Daneshmend","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.01.141_bib0310","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/00004836-199603000-00023","article-title":"Leukopenia and thrombocytopenia as adverse effects of treatment with 5-aminosalicyclic suppositories","volume":"22","author":"Casellas","year":"1996","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0315","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/0140-6736(93)90918-7","article-title":"Filgastrim for mesalazine-associated neutropenia","volume":"341","author":"Wyatt","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.01.141_bib0320","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3109\/00365528708991917","article-title":"Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides","volume":"22","author":"Turunen","year":"1987","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0325","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0140-6736(94)90108-2","article-title":"Antilymphocyte globulin for mesalazine-associated aplastic anemia","volume":"343","author":"Laidlaw","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.01.141_bib0330","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S0140-6736(94)91495-8","article-title":"Fatal aplastic anemia after mesalazine","volume":"343","author":"Abboudi","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.01.141_bib0335","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1053\/j.gastro.2005.06.021","article-title":"The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study","volume":"129","author":"Bernstein","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0340","doi-asserted-by":"publisher","first-page":"901","DOI":"10.2169\/internalmedicine.40.901","article-title":"Acute pericarditis associated with 5-aminosalicylic acid (5-ASA) treatment for severe active ulcerative colitis","volume":"40","author":"Ishikawa","year":"2001","journal-title":"Internal Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0345","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/00005176-199809000-00015","article-title":"Recurrent pericarditis due to mesalamine hypersensitivity: a pediatric case report and review of the literature","volume":"27","author":"Sentongo","year":"1998","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.1016\/j.dld.2017.01.141_bib0350","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/s00384-007-0310-2","article-title":"Sulfasalazine-induced pericarditis in a patient with ulcerative colitis without recurrence when switching to mesalazine","volume":"22","author":"Perrot","year":"2007","journal-title":"International Journal of Colorectal Disease"},{"key":"10.1016\/j.dld.2017.01.141_bib0355","first-page":"86","article-title":"The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis","volume":"4","author":"Baker","year":"2004","journal-title":"Reviews in Gastroenterological Disorders"},{"key":"10.1016\/j.dld.2017.01.141_bib0360","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1590-8658(01)80108-0","article-title":"Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects","volume":"33","author":"Di Paolo","year":"2001","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2017.01.141_bib0365","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/ecco-jcc\/jjv219","article-title":"Clinical features and HLA association of 5-aminosalicylate (5-ASA)-induced nephrotoxicity in inflammatory bowel disease","volume":"10","author":"Heap","year":"2016","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib0370","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1111\/j.1365-2036.2005.02462.x","article-title":"Experience of 5-aminosalicylate nephrotoxicity in the United Kingdom","volume":"21","author":"Muller","year":"2005","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0375","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s00384-002-0467-7","article-title":"No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases","volume":"18","author":"Dehmer","year":"2003","journal-title":"International Journal of Colorectal Disease"},{"key":"10.1016\/j.dld.2017.01.141_bib0380","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5414\/CNP61083","article-title":"Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy?","volume":"61","author":"Elseviers","year":"2004","journal-title":"Clinical Nephrology"},{"key":"10.1016\/j.dld.2017.01.141_bib0385","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.crohns.2007.11.002","article-title":"European evidence-based consensus on the management of ulcerative colitis: current management","volume":"2","author":"Travis","year":"2008","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib0390","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/ajg.2009.727","article-title":"Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee","volume":"105","author":"Kornbluth","year":"2010","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0395","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1053\/j.gastro.2004.03.016","article-title":"5-Aminosalicylic acids and the risk of renal disease: a large British epidemiologic study","volume":"126","author":"Van Staa","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0400","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1365-2036.2000.00683.x","article-title":"Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease","volume":"14","author":"Corrigan","year":"2000","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0405","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/oxfordjournals.ndt.a027349","article-title":"Mesalazine associated interstitial nephritis","volume":"11","author":"World","year":"1996","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.dld.2017.01.141_bib0410","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1046\/j.1365-2036.2002.01216.x","article-title":"Review article: monitoring for drug side-effects in inflammatory bowel disease","volume":"16","author":"Cunliffe","year":"2002","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0415","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/ibd.20099","article-title":"5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review","volume":"13","author":"Gisbert","year":"2007","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib0420","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2165\/00002018-199614020-00001","article-title":"Drugs during pregnancy: an issue of risk classification and information to prescribers","volume":"14","author":"Sannerstedt","year":"1996","journal-title":"Drug Safety"},{"key":"10.1016\/j.dld.2017.01.141_bib0425","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1046\/j.1365-2036.1998.00417.x","article-title":"Foetal outcome in women with inflammatory bowel disease treated during pregnancy with oral mesalazine microgranules","volume":"12","author":"Marteau","year":"1998","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0430","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0016-5085(98)70628-6","article-title":"The safety of mesalamine in human pregnancy: a prospective controlled cohort study","volume":"114","author":"Diav-Citrin","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0435","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/S0140-6736(94)90493-6","article-title":"Mesalazine during pregnancy","volume":"344","author":"Marteau","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.01.141_bib0440","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1136\/gut.43.3.316","article-title":"Exposure to mesalamine during pregnancy increased preterm deliveries (but not birth defects) and decreased birth weight","volume":"43","author":"Sachar","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib0445","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1136\/gut.52.2.243","article-title":"Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study","volume":"52","author":"N\u00f8rg\u00e5rd","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib0450","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/j.1572-0241.2007.01216.x","article-title":"Therapeutic drug use in women with Crohn\u2019s disease and birth outcomes: a Danish nationwide cohort study","volume":"102","author":"N\u00f8rg\u00e5rd","year":"2007","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0455","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1053\/j.gastro.2013.09.061","article-title":"Limited risks of major congenital anomalies in children of mothers with IBD and effects of medications","volume":"146","author":"Ban","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0460","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1111\/j.1572-0241.2005.41983_8.x","article-title":"Safety of high doses of mesalazine during pregnancy","volume":"100","author":"Marteau","year":"2005","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0465","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.reprotox.2007.11.010","article-title":"Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis","volume":"25","author":"Rahimi","year":"2008","journal-title":"Reproductive Toxicology"},{"key":"10.1016\/j.dld.2017.01.141_bib0470","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.bpg.2007.05.002","article-title":"Drug therapy for inflammatory bowel disease in pregnancy and the puerperium","volume":"21","author":"Moffatt","year":"2007","journal-title":"Best Practice & Research Clinical Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0475","unstructured":"Position paper Agenzia Italiana per il Farmaco (AIFA), 2013."},{"key":"10.1016\/j.dld.2017.01.141_bib0480","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2147\/IBPC.S9486","article-title":"Hypertension and other morbidities with Cushing\u2019s syndrome associated with corticosteroids: a review","volume":"4","author":"Peppa","year":"2011","journal-title":"Integrated Blood Pressure Control"},{"key":"10.1016\/j.dld.2017.01.141_bib0485","doi-asserted-by":"publisher","first-page":"291","DOI":"10.2147\/vhrm.2005.1.4.291","article-title":"Cardiovascular consequences of cortisol excess","volume":"1","author":"Whitworth","year":"2005","journal-title":"Vascular Health and Risk Management"},{"key":"10.1016\/j.dld.2017.01.141_bib0490","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib0495","first-page":"CD007698","article-title":"Oral budesonide for induction of remission in ulcerative colitis","author":"Sherlock","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.dld.2017.01.141_bib0500","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0505","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib0510","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s001980200108","article-title":"The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis","volume":"13","author":"van Staa","year":"2002","journal-title":"Osteoporosis International"},{"key":"10.1016\/j.dld.2017.01.141_bib0515","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-011-0060-1","article-title":"Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA)","volume":"6","author":"Str\u00f6m","year":"2011","journal-title":"Archives of Osteoporosis"},{"key":"10.1016\/j.dld.2017.01.141_bib0520","first-page":"327","article-title":"Osteonecrosis in inflammatory bowel diseases: a review of the literature","volume":"72","author":"Hauzeur","year":"2009","journal-title":"Acta Gastro-Enterologica Belgica"},{"key":"10.1016\/j.dld.2017.01.141_bib0525","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1111\/j.1572-0241.2008.01942.x","article-title":"Preoperative steroid use and risk of postoperative complications in patients with inflammatory bowel disease undergoing abdominal surgery","volume":"103","author":"Subramanian","year":"2008","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0530","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0016-5085(03)00883-7","article-title":"Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients","volume":"125","author":"Aberra","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0535","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/ibd.20863","article-title":"Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis","volume":"15","author":"Ferrante","year":"2009","journal-title":"Inflammatory Bowel Disease"},{"key":"10.1016\/j.dld.2017.01.141_bib0540","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.crohns.2010.07.004","article-title":"European evidenced-based consensus on reproduction in inflammatory bowel disease","volume":"4","author":"van der Woude","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib0545","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/j.1365-2036.2011.04794.x","article-title":"Pregnancy outcome in inflammatory bowel disease: prospective European case-control ECCO-EpiCom study, 2003\u20132006","volume":"34","author":"Bortoli","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0550","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/bjophthalmol-2011-301189","article-title":"The prevalence of primary angle closure glaucoma in European derived populations: a systematic review","volume":"96","author":"Day","year":"2012","journal-title":"British Journal of Ophthalmology"},{"key":"10.1016\/j.dld.2017.01.141_bib0555","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","year":"2016","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.dld.2017.01.141_bib0560","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn\u2019s disease: TREAT registry","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib0565","first-page":"65","article-title":"Low bioavailability and traditional systemic steroids in IBD: can the former take over the latter?","volume":"22","author":"Fasc\u00ec Spurio","year":"2013","journal-title":"Journal of Gastrointestinal and Liver Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib0570","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.crohns.2009.09.007","article-title":"Clinical trial: preliminary efficacy and safety study of a new Budesonide-MMX\u00ae 9mg extended-release tablets in patients with active left-sided ulcerative colitis","volume":"4","author":"D\u2019Haens","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib0575","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJM199409293311303","article-title":"Oral budesonide for active Crohn\u2019s disease. Canadian Inflammatory Bowel Disease Study Group","volume":"331","author":"Greenberg","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0580","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1111\/j.1572-0241.2002.05835.x","article-title":"Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn\u2019s disease: a randomized placebo-controlled study in the United States","volume":"97","author":"Tremaine","year":"2002","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0585","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1053\/j.gastro.2010.11.004","article-title":"Budesonide 9mg is at least as effective as mesalamine 4.5g in patients with mildly to moderately active Crohn\u2019s disease","volume":"140","author":"Tromm","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0590","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1056\/NEJM199808063390603","article-title":"A comparison of budesonide and mesalamine for active Crohn\u2019s disease. International Budesonide-Mesalamine Study Group","volume":"339","author":"Thomsen","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0595","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJM199409293311304","article-title":"A comparison of budesonide with prednisolone for active Crohn\u2019s disease","volume":"331","author":"Rutgeerts","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0600","first-page":"905","article-title":"Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn\u2019s disease. German\/Austrian Budesonide Study Group","volume":"8","author":"Gross","year":"1996","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib0605","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/gut.41.2.209","article-title":"Oral budesonide is as effective as oral prednisolone in active Crohn\u2019s disease. The Global Budesonide Study Group","volume":"41","author":"Campieri","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib0610","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/S0016-5085(98)70254-9","article-title":"Budesonide versus prednisone in the treatment of active Crohn\u2019s disease. The Israeli Budesonide Study Group","volume":"115","author":"Bar-Meir","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0615","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/00042737-200401000-00008","article-title":"Budesonide versus prednisolone for the treatment of active Crohn\u2019s disease in children: a randomized, double-blind, controlled, multicentre trial","volume":"16","author":"Escher","year":"2004","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib0620","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1053\/j.gastro.2012.08.003","article-title":"Once-daily budesonide MMX\u00ae extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0625","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/gutjnl-2012-304258","article-title":"Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study","volume":"63","author":"Travis","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib0630","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.crohns.2010.11.006","article-title":"3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial","volume":"5","author":"Gross","year":"2011","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib0635","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1053\/gast.1996.v110.pm8964395","article-title":"Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis","volume":"110","author":"L\u00f6fberg","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0640","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/ecco-jcc\/jjv101","article-title":"Budesonide MMX for the induction of remission of mild to moderate ulcerative colitis: a pooled safety analysis","volume":"9","author":"Lichtenstein","year":"2015","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib0645","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1038\/ajg.2011.70","article-title":"Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis","volume":"106","author":"Ford","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0650","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1046\/j.1365-2036.2002.01298.x","article-title":"Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study","volume":"16","author":"Rizzello","year":"2002","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0655","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/ajg.2015.114","article-title":"Oral prolonged release beclomethasone dipropionate and prednisone in the treatment of active ulcerative colitis: results from a double-blind, randomized, Parallel Group Study","volume":"110","author":"Van Assche","year":"2015","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0660","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1053\/gast.1996.v110.pm8536887","article-title":"Oral budesonide as maintenance treatment for Crohn\u2019s disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group","volume":"110","author":"Greenberg","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0665","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1136\/gut.39.1.82","article-title":"Budesonide prolongs time to relapse in ileal and ileocaecal Crohn\u2019s disease. A placebo controlled one year study","volume":"39","author":"L\u00f6fberg","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib0670","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1136\/gut.42.4.493","article-title":"Low dose oral pH modified release budesonide for maintenance of steroid induced remission in Crohn\u2019s disease. The Budesonide Study Group","volume":"42","author":"Gross","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib0675","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2036.2005.02338.x","article-title":"Budesonide as maintenance treatment in Crohn\u2019s disease: a placebo-controlled trial","volume":"21","author":"Hanauer","year":"2005","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0680","first-page":"CD002913","article-title":"Budesonide for maintenance of remission in Crohn\u2019s disease","volume":"21","author":"Kuenzig","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.dld.2017.01.141_bib0685","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0016-5085(99)70125-3","article-title":"Oral budesonide for prevention of postsurgical recurrence in Crohn\u2019s disease. The IOIBD Budesonide Study Group","volume":"116","author":"Hellers","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0690","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/00042737-199903000-00011","article-title":"Low-dose budesonide treatment for prevention of postoperative recurrence of Crohn\u2019s disease: a multicentre randomized placebo-controlled trial. German Budesonide Study Group","volume":"11","author":"Ewe","year":"1999","journal-title":"European Journal of Gastroenterology & Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib0695","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S1542-3565(04)00662-7","article-title":"Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn\u2019s disease","volume":"3","author":"Schoon","year":"2005","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib0700","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.dld.2010.12.001","article-title":"Beclomethasone dipropionate in Crohn\u2019s ileitis: a randomised, double-blind trial","volume":"43","author":"Prantera","year":"2011","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2017.01.141_bib0705","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1046\/j.1365-2036.1998.00321.x","article-title":"Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn\u2019s disease","volume":"12","author":"D\u2019Haens","year":"1998","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0710","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/j.1572-0241.2002.05609.x","article-title":"Bone mineral density in Crohn\u2019s disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapy","volume":"97","author":"Cino","year":"2002","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0715","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/j.1365-2036.2008.03891.x","article-title":"Oral budesonide for maintenance of remission of Crohn\u2019s disease: a pooled safety analysis","volume":"15","author":"Lichtenstein","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0720","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/ibd.20640","article-title":"Budesonide induction and maintenance therapy for Crohn\u2019s disease during pregnancy","volume":"15","author":"Beaulieu","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib0725","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2165\/00002018-200831110-00002","article-title":"Safety of inhaled budesonide: clinical manifestations of systemic corticosteroid-related adverse effects","volume":"31","author":"Christensson","year":"2008","journal-title":"Drug Safety"},{"key":"10.1016\/j.dld.2017.01.141_bib0730","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.aller.2013.03.009","article-title":"Inhaled beclomethasone in pregnant asthmatic women\u2014a systematic review","volume":"42","author":"de Aguiar","year":"2014","journal-title":"Allergologia et Immunopathologia"},{"key":"10.1016\/j.dld.2017.01.141_bib0735","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00151829-200605010-00001","article-title":"Managing asthma in expectant mothers","volume":"5","author":"Powrie","year":"2006","journal-title":"Treatments in Respiratory Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib0740","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrgastro.2013.135","article-title":"IBD medications during pregnancy and lactation","volume":"11","author":"Nielsen","year":"2014","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib0745","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/ecco-jcc\/jjw169","article-title":"3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 2: surgical management and special situations","volume":"11","author":"Gionchetti","year":"2016","journal-title":"Journal of Crohn\u2019s Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib0750","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.crohns.2012.09.005","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis: special situations","volume":"7","author":"Van Assche","year":"2013","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib0755","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1086\/515132","article-title":"Safety of long-term therapy with ciprofloxacin: data analysis of controlled clinical trials and review","volume":"28","author":"Segev","year":"1999","journal-title":"Clinical Infectious Diseases"},{"issue":"Suppl. 2","key":"10.1016\/j.dld.2017.01.141_bib0760","doi-asserted-by":"publisher","first-page":"S144","DOI":"10.1086\/428055","article-title":"Antimicrobial safety: focus on fluoroquinolones","volume":"41","author":"Owens","year":"2005","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib0765","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.cgh.2006.12.028","article-title":"Impact of Clostridium difficile on inflammatory bowel disease","volume":"5","author":"Issa","year":"2007","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib0770","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.cgh.2011.02.019","article-title":"Clinical and histopathological features of fluoroquinolone-induced liver injury","volume":"9","author":"Orman","year":"2011","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib0775","doi-asserted-by":"publisher","first-page":"465","DOI":"10.2165\/11587280-000000000-00000","article-title":"Quinolones: review of psychiatric and neurological adverse reactions","volume":"34","author":"Tom\u00e9","year":"2011","journal-title":"Drug Safety"},{"key":"10.1016\/j.dld.2017.01.141_bib0780","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1517\/14740338.4.2.299","article-title":"Fluoroquinolones and tendon disorders","volume":"4","author":"Melhus","year":"2005","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.dld.2017.01.141_bib0785","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/adc.2010.208843","article-title":"Ciprofloxacin safety in paediatrics: a systematic review","volume":"96","author":"Adefurin","year":"2011","journal-title":"Archives of Disease in Childhood"},{"key":"10.1016\/j.dld.2017.01.141_bib0790","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1136\/bmj.324.7349.1306","article-title":"Fluoroquinolones and risk of achilles tendon disorders: case-control study","volume":"324","author":"Van der Linden","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.dld.2017.01.141_bib0795","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1517\/14740338.2015.1085968","article-title":"Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration\u2019s adverse event reporting system","volume":"14","author":"Arabyat","year":"2015","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.dld.2017.01.141_bib0800","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.hrthm.2004.06.020","article-title":"Ciprofloxacin-induced acquired long QT syndrome","volume":"1","author":"Prabhakar","year":"2004","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.dld.2017.01.141_bib0805","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/0016-5085(95)90121-3","article-title":"Controlled trial of metronidazole treatment for prevention of Crohn\u2019s recurrence after ileal resection","volume":"108","author":"Rutgeerts","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0810","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/10915810701583010","article-title":"Pharmaceutical agents known to produce disulfiram-like reaction: effects on hepatic ethanol metabolism and brain monoamines","volume":"26","author":"Karamanakos","year":"2007","journal-title":"International Journal of Toxicology"},{"key":"10.1016\/j.dld.2017.01.141_bib0815","first-page":"202","article-title":"Neutropenia associated with metronidazole therapy","volume":"123","author":"Smith","year":"1980","journal-title":"Canadian Medical Association Journal"},{"key":"10.1016\/j.dld.2017.01.141_bib0820","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/WNF.0b013e3182334b35","article-title":"Metronidazole-induced central nervous system toxicity: a systematic review","volume":"34","author":"Kuriyama","year":"2011","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/j.dld.2017.01.141_bib0825","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0016-5085(80)90155-9","article-title":"Healing of perianal Crohn\u2019s disease with metronidazole","volume":"79","author":"Bernstein","year":"1980","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0830","first-page":"533","article-title":"Metronidazole therapy for Crohn\u2019s disease and associated fistulae","volume":"79","author":"Jacobovits","year":"1984","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0835","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2165\/00003495-199549030-00009","article-title":"Rifaximin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria","volume":"49","author":"Gillis","year":"1995","journal-title":"Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2017.01.141_bib0840","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000081990","article-title":"Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential","volume":"51","author":"Scarpignato","year":"2005","journal-title":"Chemotherapy"},{"key":"10.1016\/j.dld.2017.01.141_bib0845","first-page":"535","article-title":"Safety of the new quinolones in pregnancy","volume":"84","author":"Berkovitch","year":"1994","journal-title":"Obstetrics & Gynecology"},{"key":"10.1016\/j.dld.2017.01.141_bib0850","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1128\/AAC.42.6.1336","article-title":"Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study","volume":"42","author":"Loebstein","year":"1998","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.dld.2017.01.141_bib0855","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/ecco-jcc\/jju006","article-title":"The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease","volume":"9","author":"van der Woude","year":"2015","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib0860","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1053\/j.gastro.2006.04.049","article-title":"American Gastroenterological Association institute technical review on the use of gastrointestinal medications in pregnancy","volume":"131","author":"Mahadevan","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0865","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1471-0528.1998.tb10094.x","article-title":"A population based case-control teratologic study of oral metronidazole treatment during pregnancy","volume":"105","author":"Czeizel","year":"1998","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1016\/j.dld.2017.01.141_bib0870","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/0002-9378(95)90567-7","article-title":"Safety of metronidazole in pregnancy: a meta-analysis","volume":"172","author":"Burtin","year":"1995","journal-title":"American Journal of Obstetrics & Gynecology"},{"key":"10.1016\/j.dld.2017.01.141_bib0875","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.1365-2125.1997.00660.x","article-title":"Is metronidazole teratogenic? A meta-analysis","volume":"44","author":"Caro-Paton","year":"1997","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.dld.2017.01.141_bib0880","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1128\/AAC.06477-11","article-title":"Investigation of metronidazole use during pregnancy and adverse birth outcomes","volume":"56","author":"Koss","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.dld.2017.01.141_bib0885","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1136\/pgmj.2003.011973","article-title":"Effect of maternal antibiotics on breast feeding infants","volume":"80","author":"Mathew","year":"2004","journal-title":"Postgraduate Medical Journal"},{"key":"10.1016\/j.dld.2017.01.141_bib0890","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1097\/MIB.0b013e318281f28f","article-title":"Safety of thiopurine therapy in inflammatory bowel disease: long-term follow-up study of 3931 patients","volume":"19","author":"Chaparro","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib0895","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.dld.2008.03.016","article-title":"The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice","volume":"40","author":"Saibeni","year":"2008","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2017.01.141_bib0900","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1002\/ibd.21221","article-title":"Thiopurine therapy in inflammatory bowel disease patients: analyses of two 8-year intercept cohorts","volume":"16","author":"Jharap","year":"2010","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib0905","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.crohns.2011.11.007","article-title":"Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up","volume":"6","author":"Costantino","year":"2012","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib0910","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1111\/j.1572-0241.1999.01532.x","article-title":"Optimum duration of treatment with 6-mercaptopurine for Crohn\u2019s disease","volume":"94","author":"Kim","year":"1999","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0915","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jaad.2010.04.041","article-title":"The cutaneous and systemic manifestations of azathioprine hypersensitivity syndrome","volume":"65","author":"Bidinger","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1016\/j.dld.2017.01.141_bib0920","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/j.cgh.2009.07.019","article-title":"Timing of myelosuppression during thiopurine therapy for inflammatory bowel disease: implications for monitoring recommendations","volume":"7","author":"Lewis","year":"2009","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib0925","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1111\/j.1572-0241.2008.01848.x","article-title":"Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review","volume":"103","author":"Gisbert","year":"2008","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0930","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/BF02220605","article-title":"The clinical pharmacology of 6-mercaptopurine","volume":"43","author":"Lennard","year":"1992","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.dld.2017.01.141_bib0935","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1053\/gast.2002.32420","article-title":"6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease","volume":"122","author":"Dubinsky","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0940","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0140-6736(90)91745-V","article-title":"Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia","volume":"336","author":"Lennard","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.01.141_bib0945","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1111\/j.1572-0241.2006.00843.x","article-title":"Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients","volume":"101","author":"Gisbert","year":"2006","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0950","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","article-title":"Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease","volume":"118","author":"Dubinsky","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0955","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1136\/gut.39.3.401","article-title":"6-Mercaptopurine metabolism in Crohn\u2019s disease: correlation with efficacy and toxicity","volume":"39","author":"Cuffari","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib0960","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.1111\/j.1572-0241.2008.01743.x","article-title":"A 6-thioguanine nucleotide threshold level of 400pmol\/8\u00d710(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity","volume":"103","author":"Roblin","year":"2008","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0965","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1111\/j.1572-0241.2005.41900.x","article-title":"A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn\u2019s disease treated with azathioprine or 6-mercaptopurine","volume":"100","author":"Dubinsky","year":"2005","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0970","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1111\/j.1572-0241.2006.00843.x","article-title":"Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients","volume":"101","author":"Gisbert","year":"2006","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib0975","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/clpt.2010.320","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing","volume":"89","author":"Relling","year":"2011","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0980","first-page":"633","article-title":"Thiopurine S-methyltransferase testing for averting drug toxicity: a meta-analysis of diagnostic test accuracy","volume":"17","author":"Zur","year":"2016","journal-title":"Pharmacogenomics Journals"},{"key":"10.1016\/j.dld.2017.01.141_bib0985","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/j.1365-2036.2007.03421.x","article-title":"Sequential evaluation of thiopurine methyltransferase, inosine triphosphate pyrophosphatase, and HPRT1 genes polymorphisms to explain thiopurines\u2019 toxicity and efficacy","volume":"26","author":"Palmieri","year":"2007","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0990","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1365-2036.2004.02124.x","article-title":"Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease","volume":"20","author":"Winter","year":"2004","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib0995","doi-asserted-by":"publisher","first-page":"783","DOI":"10.2217\/14622416.7.5.783","article-title":"Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukaemia in Europe","volume":"7","author":"Van den Akkervan Marle","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.dld.2017.01.141_bib1000","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1017\/S0266462308080392","article-title":"Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects","volume":"24","author":"Compagni","year":"2008","journal-title":"International Journal of Technology Assessment in Health Care"},{"key":"10.1016\/j.dld.2017.01.141_bib1005","first-page":"761","article-title":"Pharmacoeconomic analyses of azathioprine methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease","volume":"24","author":"Preist","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.dld.2017.01.141_bib1010","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1155\/2005\/470863","article-title":"Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events","volume":"19","author":"Sayani","year":"2005","journal-title":"Canadian Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1015","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1365-2036.2009.04132.x","article-title":"Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease","volume":"31","author":"Bermejo","year":"2010","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1020","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/ibd.20603","article-title":"6-Mercaptopurine as an alternative to azathioprine in azathioprine-induced hepatoxicity","volume":"15","author":"Kiefer","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1025","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/apt.12511","article-title":"A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis","volume":"38","author":"Kennedy","year":"2013","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1030","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.crohns.2012.07.006","article-title":"Mercaptopurine induced hepatoportal sclerosis in a patient with Crohn\u2019s Disease","volume":"7","author":"Tuyama","year":"2013","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4292\/wjgpt.v5.i2.63","article-title":"Use of thiopurines in inflammatory bowel disease: safety issues","volume":"5","author":"Konidari","year":"2014","journal-title":"World Journal of Gastrointestinal Pharmacology and Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1040","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.3748\/wjg.v20.i13.3516","article-title":"Hepatitis B and C virus reactivation in immunosuppressed patients with inflammatory bowel disease","volume":"20","author":"Sansone","year":"2014","journal-title":"World Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1045","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1046\/j.1365-2036.2002.01156.x","article-title":"Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn\u2019s disease","volume":"16","author":"Dewit","year":"2002","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1050","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/j.1365-2036.2009.04106.x","article-title":"Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease","volume":"30","author":"Daperno","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1055","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1365-2036.2009.04221.x","article-title":"Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease","volume":"31","author":"Ansari","year":"2010","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1060","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.crohns.2010.02.009","article-title":"Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD","volume":"4","author":"Govani","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1065","doi-asserted-by":"publisher","first-page":"e0155218","DOI":"10.1371\/journal.pone.0155218","article-title":"The impact of azathioprine-associated lymphopenia on the onset of opportunistic infections in patients with inflammatory bowel disease","volume":"11","author":"V\u00f6gelin","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2017.01.141_bib1070","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1111\/j.1365-2036.2009.03973.x","article-title":"Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine","volume":"29","author":"Teksik","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1075","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1097\/01.MIB.0000225333.83861.16","article-title":"Reactive hemophagocytic syndrome complicating the treatment of inflammatory bowel disease","volume":"12","author":"James","year":"2006","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1080","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S0140-6736(94)92150-4","article-title":"Long-term neoplasia risk after azathioprine treatment in Inflammatory Bowel Disease","volume":"343","author":"Connell","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.01.141_bib1085","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1148\/radiology.153.2.6484163","article-title":"Development of lymphoma in patients with Crohn\u2019s disease","volume":"153","author":"Glick","year":"1984","journal-title":"Radiology"},{"key":"10.1016\/j.dld.2017.01.141_bib1090","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1053\/j.gastro.2013.07.035","article-title":"Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study","volume":"145","author":"Khan","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1095","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.crohns.2012.06.011","article-title":"The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results from a population-based cohort in Eastern Europe","volume":"7","author":"Lakatos","year":"2013","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1100","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S0016-5085(00)70353-2","article-title":"Azathioprine for maintenance of remission in Crohn\u2019s disease: benefits outweigh the risk of lymphoma","volume":"118","author":"Lewis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1105","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1053\/gast.2002.30328","article-title":"Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine","volume":"122","author":"Dayharsh","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1110","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib1115","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.01.141_bib1120","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1002\/ibd.21582","article-title":"Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study","volume":"17","author":"Vos","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1125","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","volume":"8","author":"Long","year":"2010","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1130","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1440-1746.2011.06865.x","article-title":"Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study","volume":"27","author":"Setshedi","year":"2012","journal-title":"Journal of Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1135","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/ibd.21484","article-title":"Nonmelanoma skin cancer in inflammatory bowel disease: a review","volume":"17","author":"Long","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1140","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1145","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/ajg.2013.451","article-title":"Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis","volume":"109","author":"Ariyaratnam","year":"2014","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1150","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/apt.13466","article-title":"Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"43","author":"Bourrier","year":"2016","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1155","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/j.1572-0241.2004.04148.x","article-title":"Early postoperative complications are not increased in patients with Crohn\u2019s disease treated perioperatively with infliximab or immunosuppressive therapy","volume":"99","author":"Colombel","year":"2004","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1160","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/00054725-200209000-00001","article-title":"Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications","volume":"8","author":"Mahadevan","year":"2002","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1165","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1093\/ecco-jcc\/jjv118","article-title":"Treating inflammatory bowel disease in pregnancy: the issues we face today","volume":"9","author":"Damas","year":"2015","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1170","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1586\/eci.10.35","article-title":"Inflammatory bowel disease and pregnancy: an update","volume":"6","author":"Kwan","year":"2010","journal-title":"Expert Review of Clinical Immunology"},{"key":"10.1016\/j.dld.2017.01.141_bib1175","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/ajg.2012.430","article-title":"Safety of thiopurines and anti-TNF-\u00e1 drugs during pregnancy in patients with inflammatory bowel disease","volume":"108","author":"Casanova","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1180","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.dld.2004.12.013","article-title":"Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement","volume":"37","author":"Caprilli","year":"2005","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2017.01.141_bib1185","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1136\/gutjnl-2012-303615","article-title":"Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease","volume":"63","author":"Jharap","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib1190","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1038\/ajg.2010.138","article-title":"Outcomes of pregnancies fathered by inflammatory bowel disease patients exposed to thiopurines","volume":"105","author":"Teruel","year":"2010","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1195","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1572-0241.2000.01846.x","article-title":"Outcome of pregnancies when fathers are treated with 6-mercaptopurine for inflammatory bowel disease","volume":"95","author":"Rajapakse","year":"2000","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1200","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/ibd.22948","article-title":"Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease","volume":"19","author":"Akbari","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1205","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJM199502023320503","article-title":"Methotrexate for the treatment of Crohn\u2019s disease. The North American Crohn\u2019s Study Group Investigators","volume":"332","author":"Feagan","year":"1995","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib1210","first-page":"CD000951","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","volume":"5","author":"Shea","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.dld.2017.01.141_bib1215","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1155\/1996\/213596","article-title":"Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up","volume":"10","author":"Malatjalian","year":"1996","journal-title":"Canadian Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1220","first-page":"1337","article-title":"Methotrexate-induced chronic liver injury: guidelines for detection and prevention. The ACG Committee on FDA-related matters. American College of Gastroenterology","volume":"83","author":"Lewis","year":"1988","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1225","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/j.1365-2036.2011.04925.x","article-title":"Efficacy and tolerability of methotrexate therapy for refractory Crohn\u2019s disease: a large single-centre experience","volume":"35","author":"Suares","year":"2012","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1230","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/j.1365-2036.2005.02331.x","article-title":"Oral methotrexate in ulcerative colitis","volume":"21","author":"Cummings","year":"2005","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1235","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/MCG.0b013e3181f593f9","article-title":"The safety and tolerability of methotrexate for treating patients with Crohn\u2019s disease","volume":"45","author":"Chande","year":"2011","journal-title":"Journal of Clinical Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1240","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/ibd.21820","article-title":"Incidence of liver toxicity in inflammatory bowel disease patients treated with methotrexate: a meta-analysis of clinical trials","volume":"18","author":"Khan","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1245","first-page":"1730","article-title":"Methotrexate in Crohn\u2019s disease: long-term efficacy and toxicity","volume":"95","author":"Lemann","year":"2000","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1250","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1111\/j.1572-0241.2000.03287.x","article-title":"Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease","volume":"95","author":"Te","year":"2000","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1255","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3109\/s10165-011-0521-9","article-title":"Reactivation of hepatitis B virus in a hepatitis B surface antigen-negative patient with rheumatoid arthritis treated with methotrexate","volume":"22","author":"Watanabe","year":"2012","journal-title":"Modern Rheumatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1260","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3109\/00365521.2011.647412","article-title":"Evaluation of liver fibrosis by transient elastography (Fibroscan(R)) in patients with inflammatory bowel disease treated with methotrexate: a multicentric trial","volume":"47","author":"Barbero-Villares","year":"2012","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1265","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/art.1780370304","article-title":"Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology","volume":"37","author":"Kremer","year":"1994","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1270","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.5694\/j.1326-5377.1971.tb92712.x","article-title":"Methotrexate-induced congenital malformations","volume":"2","author":"Powell","year":"1971","journal-title":"Medical Journal of Australia"},{"key":"10.1016\/j.dld.2017.01.141_bib1275","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.dld.2011.09.015","article-title":"The use of methotrexate for treatment of inflammatory bowel disease in clinical practice","volume":"44","author":"Saibeni","year":"2012","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2017.01.141_bib1280","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00054725-199503000-00006","article-title":"A critical review of cyclosporine therapy in inflammatory bowel disease","volume":"1","author":"Sandborn","year":"1995","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1285","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib1290","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","article-title":"European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"3","author":"Rahier","year":"2009","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1295","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1097\/00042737-200501000-00016","article-title":"Cyclosporin use in acute ulcerative colitis: a long-term experience","volume":"17","author":"Campbell","year":"2005","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2017.01.141_bib1300","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/ndt\/gfm085","article-title":"Malignancies in renal transplantation: an unmet medical need","volume":"22","author":"Dantal","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.dld.2017.01.141_bib1305","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3109\/09546634.2011.590792","article-title":"Cyclosporine and skin cancer: an international dermatologic perspective over 25 years of experience. A comprehensive review and pursuit to define safe use of cyclosporine in dermatology","volume":"23","author":"Muellenhoff","year":"2012","journal-title":"Journal of Dermatological Treatment"},{"key":"10.1016\/j.dld.2017.01.141_bib1310","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/1476-4598-12-98","article-title":"Cancer risk in immune-mediated inflammatory diseases (IMID)","volume":"12","author":"Beyaert","year":"2013","journal-title":"Molecular Cancer"},{"key":"10.1016\/j.dld.2017.01.141_bib1315","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1345\/aph.1H219","article-title":"Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease","volume":"41","author":"Masunaga","year":"2007","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1016\/j.dld.2017.01.141_bib1320","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib1325","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1365-2133.2005.07021.x","article-title":"A population-based study of skin cancer incidence and prevalence in renal transplant recipients","volume":"154","author":"Moloney","year":"2006","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1330","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0140-6736(97)08496-1","article-title":"Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomized comparison of two cyclosporin regimens","volume":"351","author":"Dantal","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.01.141_bib1335","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/BF02234594","article-title":"Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications","volume":"44","author":"Hyde","year":"2001","journal-title":"Diseases of the Colon & Rectum"},{"key":"10.1016\/j.dld.2017.01.141_bib1340","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s10350-005-0128-3","article-title":"Intravenous cyclosporine for the treatment of severe steroid refractory ulcerative colitis: what is the cost?","volume":"48","author":"Poritz","year":"2005","journal-title":"Diseases of the Colon & Rectum"},{"key":"10.1016\/j.dld.2017.01.141_bib1345","first-page":"1337","article-title":"Pregnancy outcome in female liver transplant recipients","volume":"43","author":"Costa","year":"2011","journal-title":"Transplant Immunology"},{"key":"10.1016\/j.dld.2017.01.141_bib1350","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/dth.12069","article-title":"Dermatological medication effects on male fertility","volume":"26","author":"Millsop","year":"2013","journal-title":"Dermatologic Therapy"},{"key":"10.1016\/j.dld.2017.01.141_bib1355","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ibd.21154","article-title":"Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding","volume":"16","author":"Gisbert","year":"2010","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1360","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.3109\/14767058.2011.634461","article-title":"Pregnancy outcomes after kidney transplantation\u2014immunosuppressive therapy comparison","volume":"25","author":"Perales-Puchalt","year":"2012","journal-title":"Maternal-Fetal and Neonatal Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib1365","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/ibd.20858","article-title":"Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy","volume":"15","author":"Branche","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1370","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/ecco-jcc\/jjv096","article-title":"Infliximab-related infusion reactions: systematic review","volume":"9","author":"Lichtenstein","year":"2015","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1375","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2017.01.141_bib1380","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","article-title":"Infliximab maintenance therapy for fistulizing Crohn\u2019s disease","volume":"350","author":"Sands","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib1385","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1390","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1111\/j.1365-2036.2008.03882.x","article-title":"The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up","volume":"29","author":"Lees","year":"2009","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1395","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1111\/j.1572-0241.2003.07457.x","article-title":"The incidence and management of infusion reactions to infliximab: a large center experience","volume":"98","author":"Cheifetz","year":"2003","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1400","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/gut.2008.163642","article-title":"Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single centre cohort study","volume":"58","author":"Fidder","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib1405","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1410","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2036.2011.04682.x","article-title":"Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease","volume":"34","author":"Steenholdt","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1415","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1111\/j.1572-0241.2002.05784.x","article-title":"Infliximab retreatment in adults and children with Crohn\u2019s disease: risk factors for the development of delayed severe systemic reaction","volume":"97","author":"Kugathasan","year":"2002","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1420","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/apt.13671","article-title":"The efficacy and safety of either infliximab or adalimumab in 362 patients with anti-TNF-\u03b1 na\u00efve Crohn\u2019s disease","volume":"44","author":"Narula","year":"2016","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1425","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/ibd.20476","article-title":"Episodic infliximab treatment induces infusion reactions","volume":"14","author":"Magro","year":"2008","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1430","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1053\/j.gastro.2003.11.014","article-title":"Comparison of scheduled and episodic treatment strategies of infliximab in Crohn\u2019s disease","volume":"126","author":"Rutgeerts","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1435","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.MIB.0000436951.80898.6d","article-title":"Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"O\u2018Meara","year":"2014","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1440","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1111\/j.1572-0241.2007.01638.x","article-title":"Tumor necrosis factor-alpha binding capacity and anti-Infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of Infliximab in Crohn\u2019s disease","volume":"103","author":"Ainsworth","year":"2008","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1445","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/ibd.20899","article-title":"Incidence and clinical significance of immunogenicity to infliximab in Crohn\u2019s disease: a critical systematic review","volume":"15","author":"Cassinotti","year":"2009","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1450","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1586\/eci.10.90","article-title":"Acute infusion reactions induced by monoclonal antibody therapy","volume":"7","author":"Maggi","year":"2011","journal-title":"Expert Review of Clinical Immunology"},{"key":"10.1016\/j.dld.2017.01.141_bib1455","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/j.1365-2036.2012.04997.x","article-title":"The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD","volume":"35","author":"Ben-Horin","year":"2012","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1460","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib1465","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/apt.12389","article-title":"Meta-analysis: rapid infliximab infusions are safe","volume":"38","author":"Neef","year":"2013","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1470","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn\u2019s disease: a randomized controlled trial","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1475","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/01.MIB.0000158166.88238.ea","article-title":"Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium","volume":"11","author":"Jacobstein","year":"2005","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1480","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib1485","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn\u2019s disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1490","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1053\/j.gastro.2013.05.048","article-title":"Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1495","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2013.06.010","article-title":"Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis","volume":"146","author":"Sandborn","year":"2014","journal-title":"Gastroenterolog y"},{"key":"10.1016\/j.dld.2017.01.141_bib1500","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1007\/s00296-011-2212-4","article-title":"Stevens\u2013Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease","volume":"33","author":"Mounach","year":"2013","journal-title":"Rheumatology International"},{"key":"10.1016\/j.dld.2017.01.141_bib1505","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.crohns.2012.02.019","article-title":"Reversible Henoch\u2013Sch\u00f6nlein purpura complicating adalimumab therapy","volume":"6","author":"Marques","year":"2012","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"10","key":"10.1016\/j.dld.2017.01.141_bib1510","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1515","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.crohns.2013.03.011","article-title":"ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)","volume":"7","author":"Danese","year":"2013","journal-title":"Journal of Crohn\u2019s and Colitis"},{"issue":"11","key":"10.1016\/j.dld.2017.01.141_bib1520","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1093\/ecco-jcc\/jjw090","article-title":"Changes in biosimilar knowledge among European Crohn\u2019s Colitis Organization (ECCO) members: a updated survey","volume":"10","author":"Danese","year":"2016","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1525","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1136\/gutjnl-2012-303824","article-title":"Biosimilars in IBD: hope or expectation?","volume":"62","author":"Gecse","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib1530","unstructured":"AIFA. Position paper su farmaci biosimilari. http:\/\/www.agenziafarmaco.gov. 2228 it\/it\/content\/position-paper-sui-farmaci-biosimilari-28052013 [Accessed 28 2229 May 2013]. 2230; 2013."},{"key":"10.1016\/j.dld.2017.01.141_bib1535","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.dld.2014.07.019","article-title":"Statements of the Italian Group for inflammatory bowel disease","volume":"46","author":"Annese","year":"2014","journal-title":"Digestive and Liver Disease"},{"key":"10.1016\/j.dld.2017.01.141_bib1540","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MIB.0000000000000995","article-title":"The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar","volume":"23","author":"Fiorino","year":"2017","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1545","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11938-013-0004-5","article-title":"Therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease","volume":"12","author":"Scott","year":"2014","journal-title":"Current Treatment Options in Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1550","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib1555","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1136\/gut.2008.163683","article-title":"Dermatological complications and safety of anti-TNF treatments","volume":"58","author":"Kerbleski","year":"2009","journal-title":"Gut"},{"issue":"Suppl. C","key":"10.1016\/j.dld.2017.01.141_bib1560","doi-asserted-by":"publisher","first-page":"29C","DOI":"10.1155\/2000\/698523","article-title":"Long term safety of infliximab","volume":"14","author":"Schaible","year":"2000","journal-title":"Canadian Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1565","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune diseases induced by TNF-targeted therapies","volume":"22","author":"Ramos-Casals","year":"2008","journal-title":"Best Practice & Research Clinical Rheumatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1570","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2133.1982.tb01731.x","article-title":"Further evidence for an association between psoriasis, Crohn\u2019s disease and ulcerative colitis","volume":"106","author":"Yates","year":"1982","journal-title":"British Journal of Dermatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1575","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","article-title":"Combined analysis of genome-wide association studies for Crohn disease and psoriasis identifies seven shared susceptibility loci","volume":"90","author":"Ellinghaus","year":"2012","journal-title":"American Journal of Human Genetics"},{"key":"10.1016\/j.dld.2017.01.141_bib1580","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1111\/j.1365-2036.2011.04866.x","article-title":"Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature","volume":"34","author":"Cullen","year":"2011","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1585","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.crohns.2013.10.013","article-title":"The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series","volume":"8","author":"Afzal","year":"2014","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1590","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.crohns.2011.10.007","article-title":"Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases","volume":"6","author":"Guerra","year":"2012","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1595","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M15-0729","article-title":"Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study","volume":"164","author":"Cleynen","year":"2016","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib1600","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/ajg.2015.205","article-title":"Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience","volume":"110","author":"Fr\u00e9ling","year":"2015","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1605","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1159\/000107622","article-title":"Cutaneous manifestations in inflammatory bowel diseases: eight cases of psoriasis induced by anti-tumor-necrosis-factor antibody therapy","volume":"215","author":"Passarini","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1610","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.crohns.2013.01.009","article-title":"Dermatological adverse reactions during anti-TNF treatments: focus on inflammatory bowel disease","volume":"7","author":"Mocci","year":"2013","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1615","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/apt.13352","article-title":"Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study","volume":"42","author":"Pugliese","year":"2015","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1620","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1136\/ard.2007.087288","article-title":"BSRBR rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register","volume":"68","author":"Harrison","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1625","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1136\/ard.62.9.829","article-title":"Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?","volume":"62","author":"Baeten","year":"2003","journal-title":"Rheumatic Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1630","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/gutjnl-2013-304683","article-title":"Anti-TNF and skin inflammation in IBD: a new paradox in gastroenterology?","volume":"63","author":"Niess","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib1635","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.crohns.2013.10.013","article-title":"The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: a single academic center case series","volume":"8","author":"Afzali","year":"2014","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1640","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17 A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment","volume":"63","author":"Tillack","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib1645","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/apt.12491","article-title":"Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease","volume":"38","author":"Moran","year":"2013","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1650","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1007\/s00296-012-2524-z","article-title":"Tumour necrosis factor-alpha inhibitor-induced hepatic injury in patients with rheumatoid arthritis: two case reports and an analysis of the laboratory data from the Slovenian national biologicals registry","volume":"33","author":"Perdan-Pirkmajer","year":"2013","journal-title":"Rheumatology International"},{"key":"10.1016\/j.dld.2017.01.141_bib1655","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1111\/tri.12185","article-title":"Fulminant hepatic failure necessitating transplantation following the initiation of infliximab therapy: a cautionary tale times two","volume":"26","author":"Rowe","year":"2013","journal-title":"Transplant International"},{"key":"10.1016\/j.dld.2017.01.141_bib1660","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3899\/jrheum.111391","article-title":"Hepatic steatosis and disease activity in subjects with psoriatic arthritis receiving tumor necrosis factor-\u03b1 blockers","volume":"39","author":"Di Minno","year":"2012","journal-title":"Journal of Rheumatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1665","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2310\/7750.2009.09007","article-title":"Drug-induced hepatitis and lupus during infliximab treatment for psoriasis: case report and literature review","volume":"14","author":"Poulin","year":"2010","journal-title":"Journal of Cutaneous Medicine and Surgery"},{"key":"10.1016\/j.dld.2017.01.141_bib1670","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/ibd.21336","article-title":"Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-\u03b1) use for inflammatory bowel disease","volume":"17","author":"Coffin","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1675","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/01.MIB.0000437496.07181.4c","article-title":"Prednisolone but not infliximab aggravates the upregulated hepatic nitrogen elimination in patients with active inflammatory bowel disease","volume":"20","author":"Thomsen","year":"2014","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1680","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1365-2036.2012.05189.x","article-title":"Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy","volume":"36","author":"Bessissow","year":"2012","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1685","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.crohns.2012.01.014","article-title":"Anti-TNF therapy induced immune neutropenia in Crohns disease\u2014report of 2 cases and review of literature","volume":"6","author":"Sebastian","year":"2012","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1690","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/rheumatology\/ket233","article-title":"The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis","volume":"52","author":"Furst","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1695","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.crohns.2007.08.005","article-title":"Intravenous iron therapy restores functional iron deficiency induced by infliximab","volume":"1","author":"Katsanos","year":"2007","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1700","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s10067-012-2113-2","article-title":"New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review","volume":"32","author":"Matsumoto","year":"2013","journal-title":"Clinical Rheumatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1705","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1007\/s00296-011-2216-0","article-title":"A case of leukoencephalopathy associated with adalimumab-treated rheumatoid arthritis and a review of literature","volume":"32","author":"Ryu","year":"2012","journal-title":"Rheumatology International"},{"key":"10.1016\/j.dld.2017.01.141_bib1710","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.autrev.2013.09.002","article-title":"Demyelination and other neurological adverse events after anti-TNF therapy","volume":"13","author":"Kaltsonoudis","year":"2014","journal-title":"Autoimmunity Reviews"},{"key":"10.1016\/j.dld.2017.01.141_bib1715","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/MAJ.0b013e31822b7bb8","article-title":"Neurological deficits during treatment with tumor necrosis factor-alpha antagonists","volume":"342","author":"Nozaki","year":"2011","journal-title":"American Journal of the Medical Sciences"},{"key":"10.1016\/j.dld.2017.01.141_bib1720","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2011.03.004","article-title":"Tumor necrosis factor alpha (TNF-\u03b1), anti-TNF-\u03b1 and demyelination revisited: an ongoing story","volume":"234","author":"Caminero","year":"2011","journal-title":"Journal of Neuroimmunology"},{"key":"10.1016\/j.dld.2017.01.141_bib1725","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1111\/apt.13083","article-title":"Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed","volume":"41","author":"Gisbert","year":"2015","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1730","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","article-title":"Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease","volume":"148","author":"Vande Casteele","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1735","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1038\/ajg.2011.211","article-title":"The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn\u2019s and Colitis Organisation: safety","volume":"106","author":"an Assche","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1740","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/gut.2010.224154","article-title":"Guidelines for the management of inflammatory bowel disease in adults","volume":"60","author":"Mowat","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib1745","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1053\/j.gastro.2013.10.046","article-title":"American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-\u03b1 biologic drugs for the induction and maintenance of remission in inflammatory Crohn\u2019s disease","volume":"145","author":"Dassopoulos","year":"2013","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.dld.2017.01.141_bib1750","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/ecco-jcc\/jjw022","article-title":"Tuberculosis in anti-tumour necrosis factor-treated inflammatory bowel disease patients after the implementation of preventive measures: compliance with recommendations and safety of retreatment","volume":"10","author":"Carpio","year":"2016","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1755","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1136\/ard.2011.151043","article-title":"Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient","volume":"70","author":"Strangfeld","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1760","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry","volume":"69","author":"Greenberg","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1765","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1136\/ard.2009.126573","article-title":"Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA","volume":"69","author":"Nam","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1770","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1136\/ard.2011.152769","article-title":"Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Galloway","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1775","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT\u2122 registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1780","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1038\/ajg.2013.138","article-title":"Opportunistic infections with anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials","volume":"108","author":"Ford","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1785","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/ecco-jcc\/jjv190","article-title":"Impact of new treatments on hospitalisation, surgery, infection, and mortality in IBD: a focus paper by the Epidemiology Committee of ECCO","volume":"10","author":"Annese","year":"2016","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1790","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1097\/MIB.0b013e318281f31c","article-title":"Epstein-Barr virus in inflammatory bowel disease-correlation with different therapeutic regimens","volume":"19","author":"Magro","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1795","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","article-title":"Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease","volume":"9","author":"Cottone","year":"2011","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1800","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00535-012-0686-9","article-title":"A prospective analysis of the incidence of and risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"48","author":"Naganuma","year":"2013","journal-title":"Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1805","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/bjs.9152","article-title":"The effect of immune therapy on surgical site infection following Crohn\u2019s disease resection","volume":"100","author":"Serradori","year":"2013","journal-title":"British Journal of Surgery"},{"key":"10.1016\/j.dld.2017.01.141_bib1810","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.crohns.2013.01.014","article-title":"Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis","volume":"7","author":"Billioud","year":"2013","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1815","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/apt.12313","article-title":"Meta-analysis: peri-operative anti-TNF\u03b1 treatment and post-operative complications in patients with inflammatory bowel disease","volume":"37","author":"Narula","year":"2013","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1820","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.crohns.2013.01.019","article-title":"The risks of post-operative complications following pre-operative infliximab therapy for Crohn\u2019s disease in patients undergoing abdominal surgery: a systematic review and meta-analysis","volume":"7","author":"Rosenfeld","year":"2013","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1825","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.5114\/aoms.2011.26612","article-title":"A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease","volume":"7","author":"Ehteshami-Afshar","year":"2011","journal-title":"Archives of Medical Science"},{"key":"10.1016\/j.dld.2017.01.141_bib1830","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/ecco-jcc\/jju028","article-title":"Risk factors for postoperative intra-abdominal septic complications after surgery in Crohn\u2019s disease: a meta-analysis of observational studies","volume":"9","author":"Huang","year":"2015","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1835","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1038\/ajg.2013.294","article-title":"Infectious and malignant complications of TNF inhibitor therapy in IBD","volume":"108","author":"Targownik","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1840","unstructured":"http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/transcripts\/3930T1.htm."},{"key":"10.1016\/j.dld.2017.01.141_bib1845","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/ajg.2011.283","article-title":"Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease","volume":"106","author":"Herrinton","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1850","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","article-title":"Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: a meta-analysis","volume":"7","author":"Siegel","year":"2009","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1855","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z","article-title":"Cancer risk in patients with inflammatory bowel disease: a population-based study","volume":"9","author":"Bernstein","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2017.01.141_bib1860","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1111\/j.1572-0241.2000.02316.x","article-title":"Risk of lymphoma in inflammatory bowel disease","volume":"95","author":"Loftus","year":"2000","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1865","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1053\/gast.2001.28703","article-title":"Inflammatory bowel disease is not associated with an increased risk of lymphoma","volume":"121","author":"Lewis","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1870","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib1875","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1097\/MIB.0b013e318281325e","article-title":"Risk factors for lymphoma in patients with inflammatory bowel disease: a case control study","volume":"19","author":"Afif","year":"2013","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1880","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2017.01.141_bib1885","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1056\/NEJMra1403718","article-title":"Cancers complicating inflammatory bowel disease","volume":"372","author":"Beaugerie","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib1890","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: inflammatory bowel disease and malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib1895","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.cgh.2014.01.021","article-title":"Risk of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review","volume":"12","author":"Dulai","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1900","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.critrevonc.2011.10.001","article-title":"Hepatosplenic gamma-delta T-cell lymphoma","volume":"83","author":"Ferreri","year":"2012","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"10.1016\/j.dld.2017.01.141_bib1905","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1910","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/ajg.2012.334","article-title":"T-cell non-Hodgkin\u2019s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha)inhibitors: results of the REFURBISH study","volume":"108","author":"Deepak","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1915","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiology and Drug Safety"},{"key":"10.1016\/j.dld.2017.01.141_bib1920","first-page":"756","article-title":"Risk of malignancy including non-melanoma skin cancer with anti-tumour necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of log-term extension studies","volume":"30","author":"Le Blay","year":"2012","journal-title":"Clinical and Experimental Rheumatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1925","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1136\/annrheumdis-2011-200622","article-title":"The influence of anti-TNF therapy upon incidence of keratinocytes skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register","volume":"71","author":"Mercer","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1930","doi-asserted-by":"publisher","first-page":"f1939","DOI":"10.1136\/bmj.f1939","article-title":"Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden","volume":"346","author":"Reachou","year":"2013","journal-title":"British Medical Journal"},{"key":"10.1016\/j.dld.2017.01.141_bib1935","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.cgh.2013.04.033","article-title":"Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1940","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and non-melanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1945","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview","volume":"2","author":"Singh","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.dld.2017.01.141_bib1950","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREAT registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1955","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1111\/apt.12491","article-title":"Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease","volume":"38","author":"Moran","year":"2013","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib1960","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2017.01.141_bib1965","doi-asserted-by":"publisher","first-page":"e48991","DOI":"10.1371\/journal.pone.0048991","article-title":"Cancer risk of anti-TNF-alpha at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses","volume":"7","author":"Moulis","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.dld.2017.01.141_bib1970","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1136\/ard.2010.149419","article-title":"Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis","volume":"70","author":"Mariette","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib1975","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/2012.jama.10857","article-title":"Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis","volume":"308","author":"Lopez-Olivo","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.dld.2017.01.141_bib1980","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1038\/ajg.2012.89","article-title":"A pooled analysis of infections, malignancy, and mortality in infliximab-and immunomodulator-treated adult patients with inflammatory bowel disease","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1985","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/ajg.2013.441","article-title":"Drug therapies and the risk of malignancy in Crohn\u2019s disease: results from the TREAT\u2122 Registry","volume":"109","author":"Lichtenstein","year":"2014","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib1990","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/art.37740","article-title":"Tumor necrosis factor alpha inhibitor therapy and cancer risk in chronic immune-mediated diseases","volume":"65","author":"Haynes","year":"2013","journal-title":"Arthritis & Rheumatology"},{"key":"10.1016\/j.dld.2017.01.141_bib1995","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1136\/gut.2005.075937","article-title":"Infliximab and newly diagnosed neoplasia in Crohn\u2019s disease: a multicentre matched pair study","volume":"55","author":"Biancone","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib2000","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/ibd.21416","article-title":"Cancer in Crohn\u2019s disease patients treated with infliximab: a long-term multicenter matched pair study","volume":"17","author":"Biancone","year":"2011","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib2005","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.cgh.2008.03.014","article-title":"Efficacy and safety of tumor necrosis factor antagonists in Crohn\u2019s disease: meta-analysis of placebo-controlled trials","volume":"6","author":"Peyrin-Biroulet","year":"2008","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib2010","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/apt.12624","article-title":"Systematic review with metaanalysis: malignancies with anti-tumour necrosis factor-\u03b1 therapy in inflammatory bowel disease","volume":"39","author":"Williams","year":"2014","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"10.1016\/j.dld.2017.01.141_bib2015","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel diseases","volume":"311","author":"Andersen","year":"2014","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.dld.2017.01.141_bib2020","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1093\/ecco-jcc\/jjw048","article-title":"Inflammatory bowel disease pheno-type as risk factor for cancer in a prospective multicentre nested case-control IG-IBD study","volume":"10","author":"Biancone","year":"2016","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib2025","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.crohns.2010.07.004","article-title":"European evidenced-based consensus on reproduction in inflammatory bowel disease","volume":"4","author":"van der Woude","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib2030","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/rheumatology\/ket409","article-title":"Biologic therapies and pregnancy: the story so far","volume":"53","author":"Hyrich","year":"2014","journal-title":"Rheumatology"},{"issue":"Suppl. 4","key":"10.1016\/j.dld.2017.01.141_bib2035","first-page":"A54","article-title":"Safety of infliximab in Crohn\u2019s disease: data from the 5000-patient TREAT registry","volume":"126","author":"Lichtenstein","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib2040","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","article-title":"Outcome of pregnancy in women receiving infliximab for the treatment of Crohn\u2019s disease and rheumatoid arthritis","volume":"99","author":"Katz","year":"2004","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib2045","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/01.MIB.0000440984.86659.4f","article-title":"Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children","volume":"20","author":"Bortilik","year":"2014","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib2050","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.reprotox.2013.11.004","article-title":"Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study","volume":"43","author":"Diav-Citrin","year":"2014","journal-title":"Reproductive Toxicology"},{"key":"10.1016\/j.dld.2017.01.141_bib2055","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3109\/00365521.2013.812141","article-title":"Pregnancy and newborn outcome of mothers with inflammatory bowel disease exposed to anti-TNF\u03b1 therapy during pregnancy: three-center study","volume":"48","author":"Borltlik","year":"2013","journal-title":"Scandinavian Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib2060","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/ajg.2013.171","article-title":"Safety of anti-TNG agents during pregnancy and breastfeeding in women with inflammatory bowel disease","volume":"108","author":"Gisbert","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib2065","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cgh.2012.11.011","article-title":"Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease","volume":"11","author":"Mahadevan","year":"2013","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib2070","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.cgh.2015.08.039","article-title":"Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy","volume":"14","author":"Br\u00f6ms","year":"2016","journal-title":"Clinical Gastroenterology and Hepatology"},{"issue":"1","key":"10.1016\/j.dld.2017.01.141_bib2075","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1053\/j.gastro.2016.04.002","article-title":"Concentrations of adalimumab 2585 and infliximab in mothers and newborns, and effects on infection","volume":"151","author":"Julsgaard","year":"2016","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.dld.2017.01.141_bib2080","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1136\/gutjnl-2015-309321","article-title":"Tailored anti-TNF therapy during 2588 pregnancy in patients with IBD: maternal and fetal safety","volume":"65","author":"de Lima","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib2085","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/S1542-3565(04)00238-1","article-title":"Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn\u2019s disease","volume":"2","author":"Hanauer","year":"2004","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib2090","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1053\/j.gastro.2013.12.025","article-title":"Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn\u2019s disease","volume":"146","author":"Osterman","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib2095","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/1042819021000035662","article-title":"Hepatosplenic T-gammadelta lymphoma in a patient with Crohn\u2019s disease treated with azathioprine","volume":"44","author":"Navarro","year":"2003","journal-title":"Lymphoma"},{"key":"10.1016\/j.dld.2017.01.141_bib2100","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","article-title":"Hepatosplenic T-cell lymphoma associated with Infliximab use in young patients treated with for inflammatory bowel disease","volume":"44","author":"Mackey","year":"2007","journal-title":"Journal of Pediatric Gastroenterology and Nutrition"},{"key":"10.1016\/j.dld.2017.01.141_bib2105","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1136\/gut.2008.163279","article-title":"Hepatosplenic T cell lymphoma in inflammatory bowel disease","volume":"57","author":"Shale","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib2110","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.crohns.2010.05.006","article-title":"Hepatosplenic T-cell lymphoma and inflammatory bowel disease","volume":"4","author":"Thai","year":"2010","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib2115","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1002\/ibd.22866","article-title":"Prognosis of lymphoma in patients following treatment with 6-mercaptopurine\/azathioprine for inflammatory bowel disease","volume":"18","author":"Sultan","year":"2012","journal-title":"Inflammatory Bowel Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib2120","doi-asserted-by":"crossref","first-page":"267","DOI":"10.15403\/jgld.2014.1121.233.mrmk","article-title":"Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-\u03b1 inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System","volume":"23","author":"McKenna","year":"2014","journal-title":"Journal of Gastrointestinal and Liver Diseases"},{"key":"10.1016\/j.dld.2017.01.141_bib2125","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1093\/ndt\/gfn292","article-title":"Sunscreens in organ transplant patients","volume":"23","author":"Ulrich","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1016\/j.dld.2017.01.141_bib2130","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1517\/14740338.2016.1145653","article-title":"A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn\u2019s disease","volume":"15","author":"Papamichael","year":"2016","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.dld.2017.01.141_bib2135","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib2140","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib2145","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1053\/j.gastro.2014.05.008","article-title":"Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed","volume":"147","author":"Sands","year":"2014","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.dld.2017.01.141_bib2150","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","article-title":"Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease","volume":"14","author":"Arniot","year":"2016","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.1016\/j.dld.2017.01.141_bib2155","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/ecco-jcc\/jjv226","article-title":"Vedolizumab effectiveness and safety over the first year of use in an IBD clinical practice","volume":"10","author":"Vivio","year":"2016","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"10.1016\/j.dld.2017.01.141_bib2160","article-title":"The safety of vedolizumab for ulcer- 2635 active colitis and Crohn\u2019s disease","author":"Colombel","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.dld.2017.01.141_bib2165","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1177\/1756283X16635081","article-title":"The role of vedolizumab in patients with moderate-to-severe Crohn\u2019s disease and ulcerative colitis","volume":"9","author":"Shahidi","year":"2016","journal-title":"Therapeutic Advances in Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib2170","doi-asserted-by":"crossref","first-page":"S502","DOI":"10.14309\/00000434-201310001-01674","article-title":"Long-term safety of vedolizumab for the treatment of ulcerative colitis or Crohn\u2019s disease","volume":"108","author":"Colombel","year":"2013","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib2175","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.1097\/MD.0000000000000326","article-title":"PRISMA\u2014efficacy and safety of vedolizumab for inflammatory bowel diseases","volume":"93","author":"Wang","year":"2014","journal-title":"Medicine"},{"key":"10.1016\/j.dld.2017.01.141_bib2180","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1038\/ajg.2011.271","article-title":"Inflammatory bowel disease of the elderly: frequently asked questions (FAQs)","volume":"106","author":"Katz","year":"2011","journal-title":"American Journal of Gastroenterology"},{"key":"10.1016\/j.dld.2017.01.141_bib2185","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn\u2019s disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"New England Journal of Medicine"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865817301457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865817301457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T21:31:29Z","timestamp":1719005489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865817301457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":437,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S1590865817301457"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2017.01.141","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2017.01.141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}